Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Finranks

Kompaniya

  • Biz haqimizda

Biz bilan bog'lanish

  • [email protected]

Bizni kuzating

  • Instagram
  • Telegram
  • LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari
  • Bosh sahifa
  • Bozorlar
  • Skriner
  • Yangiliklar
  • Biz haqimizda
  1. Home
  3. GILD
G

Gilead Sciences, Inc. (GILD)

NMS – Real vaqt narxi. Valyuta: USD

134.25

-2.63 (-1.92%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

133.88

-0.37 (-0.28%)

Bozordan keyin: Mar 27, 2026, 7:51 PM EDT

  • Umumiy
  • Yangiliklar
  • Grafik
  • Hisobotlar
  • Dividendlar
  • Kutilma
  • Egalik
  • Profil
Why Gilead Sciences (GILD) Dipped More Than Broader Market Today
27.03.2026

Why Gilead Sciences (GILD) Dipped More Than Broader Market Today

Gilead Sciences (GILD) closed the most recent trading day at $134.25, moving 1.92% from the previous trading session.

Here's Why Gilead Sciences (GILD) is a Strong Value Stock
27.03.2026

Here's Why Gilead Sciences (GILD) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
27.03.2026

Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?
27.03.2026

Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?

Gilead doubles down on acquisitions, adding immunology and CAR-T assets to diversify beyond HIV and strengthen its oncology pipeline.

Gilead Strengthens Inflammation Portfolio With Ouro Medicines Deal
24.03.2026

Gilead Strengthens Inflammation Portfolio With Ouro Medicines Deal

GILD expands into autoimmune therapies with an acquisition deal with Ouro Medicines, adding OM336 and advancing its push into next-gen immunology platforms.

Gilead Sciences to acquire Ouro Medicines, expanding autoimmune therapy portfolio
24.03.2026

Gilead Sciences to acquire Ouro Medicines, expanding autoimmune therapy portfolio

Gilead Sciences Inc (NASDAQ:GILD, XETRA:GIS) announced it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotech company developing T cell engager therapies for autoimmune diseases. The acquisition adds OM336 (gamgertamig), a clinical-stage BCMAxCD3 bispecific T cell engager, to Gilead's inflammation portfolio.

Gilead to Buy Ouro Medicines for $2.2 Billion. ‘Immune Reset' Is Key to Future Gains.
24.03.2026

Gilead to Buy Ouro Medicines for $2.2 Billion. ‘Immune Reset' Is Key to Future Gains.

Gilead plans to develop Ouro's lead drug candidate, gamgertamig, alongside a Belgian pharma company.

Videolar

19.03.2026
Positive
5 Stocks to Buy in a High-Risk Bull Market
27.02.2026
Positive
Johanna Mercier on Gilead's HIV prevention innovation
12.01.2026
Positive
Gilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history
21.10.2025
Neutral
Final Trade: F, HAL, MA, GILD

Press-relizlar

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
23.03.2026

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases. The acquisition adds OM336 (gamgertamig), a clinical‑stage BCMAxCD3 T cell engager, to Gilead's growing inflammation portfolio. OM336 is designed to enable rapid and deep B cell depletion following a limited subcutaneously admi.

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX
13.03.2026

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Arcellx, Inc. (NasdaqGS: ACLX) to Gilead Sciences, Inc. (NasdaqGS: GILD). Under the terms of the proposed transaction, shareholders of Arcellx will receive $115.00 per share in cash plus one contingent value right of $5.00 per share upon the achievement of certain milestones. KSF is seeking to deter.

Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia
02.03.2026

Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia

FOSTER CITY, Calif.--(BUSINESS WIRE)--GILEAD FOUNDATION AWARDS $12 MILLION TO EMPOWER COMMUNITY HEALTH WORKERS AND EXPAND HIV PREVENTION INITIATIVES ACROSS THE US.

Gilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
25.02.2026

Gilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #CROI2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at CROI 2026 showing a treatment switch to an investigational, single-tablet combination regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) was effective in people living with HIV with virological suppression, including those switching from complex multi-tablet regimens or a global guideline-recommended single-tablet regimen. The n.